A Major Need in a Rapidly Growing Market
The global female infertility market continues to expand, driven by ongoing challenges in improving implantation success in assisted reproductive technologies. Despite advances in embryo selection and laboratory techniques, implantation rates remain relatively low, suggesting that factors beyond embryo quality — including the uterine microenvironment — may be relevant in certain cases. Early research indicates that lymphatic function could be one such biological factor affecting tissue homeostasis and immune signalling in the endometrium; this remains an area of active investigation.
© 2026 by LYMPHOGENiX. All rights reserved.
Our Solution (Vessely™)
A Research-Focused Preclinical Candidate
Vessely™ is an investigational, locally administered research candidate in preclinical development. It is being evaluated in experimental models to explore whether modulation of lymphatic pathways within the uterine microenvironment is associated with biological features relevant to implantation. The programme is not intended to imply clinical readiness or therapeutic efficacy in humans at this stage, and compatibility with standard clinical IVF workflows will be assessed only if supported by future evidence.
Unlocking the Endometrium’s Lymphatic Network
In preclinical studies, Vessely™ is being investigated for its ability to modulate lymphatic pathways in the endometrium. These studies assess exploratory associations with immune regulation, fluid balance, and tissue stability — elements that are hypothesised to contribute to receptive conditions for implantation. Any implications for early pregnancy biology or clinical outcomes remain to be established through further research.
✦ Regenerates lymphatic vessels
✦ Normalizes immune signalling
✦ Stabilizes implantation environment
Robust and Reproducible Restoration of Implantation
In specific preclinical models, lymphatic modulation has been associated with implantation in treated tissue; further studies are required to rigorously define causal mechanisms.
Severe Infertility Model (IUA)
Validated large-animal model representing profound implantation failure.
One-Sided Infertility
Implantation restored exclusively in treated uterine tissue, demonstrating localized biological effect.
Reproducibility
Consistent outcomes observed across multiple animals and study repeats.
Demonstrates biological causality — not correlation.
Translational Pathway Considerations
Large-animal models are utilised to explore translational feasibility, including aspects such as dosing parameters, manufacturing considerations, and study design under controlled research conditions. Findings from these models may help inform future clinical development planning; they should not be interpreted as direct evidence of clinical outcomes or immediate human therapeutic potential. Initiation of human clinical trials has not yet occurred and remains dependent on further data and regulatory approvals.
Summary
This page outlines LYMPHOGENiX’s preclinical research into lymphatic biology and its potential relevance to reproductive health. All descriptions reflect activities and hypotheses that are under active investigation in laboratory and translational models. No product on this page, including Vessely™, is approved for clinical use or has been demonstrated to improve clinical outcomes in humans. Progression toward human research will depend on future evidence and regulatory review.